Acute Vulvovaginal Candidiasis Treatment Market

Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.

Acute Vulvovaginal Candidiasis Treatment Market contains market size and forecasts of Acute Vulvovaginal Candidiasis Treatment in Global, including the following market information:

Global Acute Vulvovaginal Candidiasis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Acute Vulvovaginal Candidiasis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Clotrimazole Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Acute Vulvovaginal Candidiasis Treatment include Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc and Amplyx Pharmaceuticals Inc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Acute Vulvovaginal Candidiasis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Acute Vulvovaginal Candidiasis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Type, 2021 (%)

Clotrimazole

Nystatin

Fluconazole

Ketoconazole

Terbinafine

Terconazole

Others

Global Acute Vulvovaginal Candidiasis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Acute Vulvovaginal Candidiasis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Acute Vulvovaginal Candidiasis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Acute Vulvovaginal Candidiasis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Acute Vulvovaginal Candidiasis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Mycovia Pharmaceuticals, Inc

Scynexis, Inc

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Grupo Ferrer Internacional, S.A

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Cidara Therapeutics, Inc

Amplyx Pharmaceuticals Inc

Pfizer, Inc.